Department of Chemical Engineering, University of Massachusetts Amherst, Amherst, MA 01003, USA.
Department of Food Science, University of Massachusetts Amherst, Amherst, MA 01003, USA.
Molecules. 2020 Mar 5;25(5):1161. doi: 10.3390/molecules25051161.
There are many areas in medicine and industry where it would be advantageous to orally deliver bioactive proteins and peptides (BPPs), including ACE inhibitors, antimicrobials, antioxidants, hormones, enzymes, and vaccines. A major challenge in this area is that many BPPs degrade during storage of the product or during passage through the human gut, thereby losing their activity. Moreover, many BPPs have undesirable taste profiles (such as bitterness or astringency), which makes them unpleasant to consume. These challenges can often be overcome by encapsulating them within colloidal particles that protect them from any adverse conditions in their environment, but then release them at the desired site-of-action, which may be inside the gut or body. This article begins with a discussion of BPP characteristics and the hurdles involved in their delivery. It then highlights the characteristics of colloidal particles that can be manipulated to create effective BPP-delivery systems, including particle composition, size, and interfacial properties. The factors impacting the functional performance of colloidal delivery systems are then highlighted, including their loading capacity, encapsulation efficiency, protective properties, retention/release properties, and stability. Different kinds of colloidal delivery systems suitable for encapsulation of BPPs are then reviewed, such as microemulsions, emulsions, solid lipid particles, liposomes, and microgels. Finally, some examples of the use of colloidal delivery systems for delivery of specific BPPs are given, including hormones, enzymes, vaccines, antimicrobials, and ACE inhibitors. An emphasis is on the development of food-grade colloidal delivery systems, which could be used in functional or medical food applications. The knowledge presented should facilitate the design of more effective vehicles for the oral delivery of bioactive proteins and peptides.
医学和工业领域有许多应用场景,通过口服递送生物活性蛋白和肽(BPPs)会很有优势,这些 BPPs 包括 ACE 抑制剂、抗菌剂、抗氧化剂、激素、酶和疫苗。这方面的一个主要挑战是,许多 BPPs 在产品储存或通过人体肠道时会降解,从而失去其活性。此外,许多 BPPs 具有不良的口感(如苦味或涩味),使其难以食用。这些挑战通常可以通过将它们封装在胶体颗粒中来克服,这些胶体颗粒可以保护它们免受环境中任何不利条件的影响,但随后可以在所需的作用部位(可能在肠道内或体内)释放它们。本文首先讨论了 BPP 的特性以及它们递送所涉及的障碍。然后强调了可以用来创建有效的 BPP 递送系统的胶体颗粒的特性,包括颗粒组成、大小和界面特性。然后突出了影响胶体递送系统功能性能的因素,包括其载药量、包封效率、保护性能、保留/释放性能和稳定性。然后回顾了适合封装 BPP 的不同类型的胶体递送系统,例如微乳液、乳液、固体脂质颗粒、脂质体和微凝胶。最后,给出了胶体递送系统用于递送特定 BPP 的一些示例,包括激素、酶、疫苗、抗菌剂和 ACE 抑制剂。重点是开发可用于功能性或医疗食品应用的食品级胶体递送系统。本文呈现的知识应该有助于设计更有效的生物活性蛋白和肽口服递送载体。